CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
combined with IL-15 superagonist (N-803) in recurrent, high grade ovarian cancer (HGOC).Names of the study therapies involved in th...
Phase 1
Boston, Massachusetts, United States and 1 other location
The goal of this clinical trial is to compare participants with ovarian, fallopian tube or primary peritoneal cancer when treated w...
Phase 2
Boston, Massachusetts, United States and 25 other locations
This study is testing whether a 6 week skills-based telehealth intervention can help ovarian cancer patients experiencing PARP inhi...
Boston, Massachusetts, United States and 1 other location
This research study is studying a combination of targeted therapies as a possible treatment for estrogen-receptor positive (ER+) endometrial cancer...
Phase 2
Boston, Massachusetts, United States and 2 other locations
of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...
Phase 3
Boston, Massachusetts, United States and 125 other locations
in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian...
Phase 2
Boston, Massachusetts, United States and 41 other locations
(PK), and pharmacodynamics (PD) of ZN-c3 in combination with niraparib and of ZN-c3 Monotherapy in subjects with platinum-resistant ovarian ....
Phase 1, Phase 2
Providence, Rhode Island, United States and 19 other locations
positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 pri...
Phase 2
Boston, Massachusetts, United States and 70 other locations
This research study is evaluating three drugs called Nivolumab, Bevacizumab, and Rucaparib as a possible treatment for relapsed Relapsed Ovarian...
Phase 2
Boston, Massachusetts, United States and 2 other locations
of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...
Phase 3
Boston, Massachusetts, United States and 92 other locations
Clinical trials
Research sites
Resources
Legal